Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trialsChee Khoon Lee, Shilo Lefresne, Yu Yang Soon, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 7, 2019
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyEmina Torlakovic, Hyun J Lim, Julien Adam, et al.
Theranostics|January 12, 2023
FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sitesWin Lwin Thuya, Li Ren Kong, Nicholas L Syn, et al.
Oncotarget|May 4, 2017
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancerSheila X Soh, Fahad J Siddiqui, John C Allen, et al.
Science Translational Medicine|August 5, 2016
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expressionKol Jia Yong, Daniela S Basseres, Robert S Welner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2017
Scientific Advances in Thoracic Oncology 2016Ross A Soo, Emily C A Stone, K Michael Cummings, et al.
Nature Medicine|March 20, 2012
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerKing Pan Ng, Axel M Hillmer, Charles T H Chuah, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLCMay-Lucie Meyer, Solange Peters, Hossein Borghaei, et al.
Pageof 16